HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (2- chlorophenyl)- 3- cyclopropylmethoxy- 4- di- fluoromethoxybenzamide

Also Known As:

FCPR16

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Cheng, Yufang: 2 articles (01/2019 - 01/2018)
2.	Huang, Chang: 2 articles (01/2019 - 01/2018)
3.	Wang, Haitao: 2 articles (01/2019 - 01/2018)
4.	Xu, Jiangping: 2 articles (01/2019 - 01/2018)
5.	Yu, Hui: 2 articles (01/2019 - 01/2018)
6.	Zhong, Jiahong: 2 articles (01/2019 - 01/2018)
7.	Zhong, Qiuping: 1 article (01/2019)
8.	Chen, Jiajia: 1 article (01/2018)
9.	Feng, Hongfang: 1 article (01/2018)
10.	Zheng, Wenhua: 1 article (01/2018)

Related Diseases

1.	Reperfusion Injury 01/01/2018 - "This study indicates that FCPR16 has protective effects against cerebral ischemia-reperfusion injury through inhibiting inflammation and apoptosis via the cAMP/CREB pathway, while it has low emetogenic potential." 01/01/2018 - "The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion."
2.	Inflammation (Inflammations) 01/01/2018 - "This study indicates that FCPR16 has protective effects against cerebral ischemia-reperfusion injury through inhibiting inflammation and apoptosis via the cAMP/CREB pathway, while it has low emetogenic potential."
3.	Brain Ischemia (Cerebral Ischemia) 01/01/2018 - "This study indicates that FCPR16 has protective effects against cerebral ischemia-reperfusion injury through inhibiting inflammation and apoptosis via the cAMP/CREB pathway, while it has low emetogenic potential."
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2018 - "Our results showed that FCPR16 treatment improved neurological function, reduced cerebral infarct volume, and attenuated brain histological changes in rats subjected to middle cerebral artery occlusion and reperfusion (MCAO/R). " 01/01/2018 - "The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion."
5.	Cerebral Infarction 01/01/2018 - "Our results showed that FCPR16 treatment improved neurological function, reduced cerebral infarct volume, and attenuated brain histological changes in rats subjected to middle cerebral artery occlusion and reperfusion (MCAO/R). "

Related Drugs and Biologics

1.	Phosphodiesterase 4 Inhibitors
2.	Type 4 Cyclic Nucleotide Phosphodiesterases
3.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Oral Administration